<DOC>
	<DOCNO>NCT01468974</DOCNO>
	<brief_summary>The purpose ESPRIT I Clinical Investigation evaluate safety performance ESPRIT BVS subject symptomatic claudication occlusive vascular disease superficial femoral ( SFA ) common external iliac artery .</brief_summary>
	<brief_title>ESPRIT I : A Clinical Evaluation Abbott Vascular ESPRIT BVS ( Bioresorbable Vascular Scaffold ) System</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Subject ≥ 18 ≤ 80 year age time sign informed consent . 2 . Subject diagnose symptomatic claudication ( RutherfordBecker Clinical Category 13 ) . For subject bilateral lesion , high RutherfordBecker Clinical Category limb consider target extremity treat trial . If limbs Rutherford Becker Clinical Category , target extremity select base investigator discretion . 3 . Subject legally authorize representative inform nature study , agree provision , able provide inform consent . 4 . Subject agree undergo protocolrequired followup examination requirement investigational site . 5 . Female subject childbearing potential must : negative pregnancy test within 14 day treatment ; nursing time study procedure agree time consent use birth control participation trial . 6 . Subject life expectancy &gt; 12 month . 7 . Subject able take clopidogrel prasugrel ( ticlopidine , subject take clopidogrel prasugrel ) acetylsalicylic acid ( aspirin ) . 8 . Subject must agree participate clinical investigation period 12 month follow index procedure . This include clinical trial medication invasive procedure . Questionnairebased study , study noninvasive require medication allow . Angiographic Inclusion Criteria 1 . A single de novo native disease segment superficial femoral ( SFA ) common external iliac artery target extremity locate within follow anatomical parameter : Iliac Proximal margin target lesion ≥ 2.5 cm distal aortic bifurcation common iliac artery Distal margin target lesion ≥ 1.5 cm proximal location inguinal ligament SFA Proximal margin target lesion ≥ 1 cm distal common femoral artery bifurcation Distal margin target lesion ≤ 25 cm distal common femoral artery bifurcation 2 . Vessel diameter ≥ 5.5 mm ≤ 6.5 mm evaluate online quantitative vascular angiography ( QVA ) predilatation per core laboratory guideline 3 . Target lesion ≥ 50 % DS 4 . Target lesion length ≤ 50 mm 5 . Patent inflow artery free significant lesion ( ≥ 50 % DS &lt; 100 % DS ) confirm angiography ( treatment target lesion acceptable successful treatment inflow artery lesion ) 6 . Patent popliteal artery free significant lesion ( ≥ 50 % DS ) least one patent distal outflow artery ( anterior tibial , posterior tibial , peroneal ) provide inline circulation lower leg foot , confirm angiography 1 . A platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 ; white blood cell count ( WBC ) &lt; 3,000 cells/mm3 ; hemoglobin &lt; 10.0 g/dL 2 . Acute chronic renal dysfunction ( creatinine &gt; 2.5 mg/dl &gt; 176μmol/L ) 3 . Severe liver impairment define total bilirubin ≥ 3 mg/dl two time increase normal level serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) . 4 . Known allergy follow : aspirin , clopidogrel , prasugrel ticlopidine , heparin , contrast agent ( adequately premedicated ) , drug similar everolimus ( i.e . tacrolimus , sirolimus , zotarolimus ) macrolides . 5 . Subject require planned procedure would necessitate discontinuation clopidogrel , prasugrel ticlopidine . 6 . Subject require treatment drug elute stent ( DES ) drug coat balloon ( DCB ) within 6 month pre postindex procedure . 7 . Subject unable walk . 8 . Subject undergone noniliac percutaneous intervention , e.g . coronary , carotid , &lt; 30 day prior plan index procedure . 9 . Subject receive , wait list , organ transplant . 10 . Subject chronic hemodialysis . 11 . Subject uncontrolled diabetes mellitus ( DM ) ( HbA1c ≥ 7.0 % ) . 12 . Subject myocardial infarction ( MI ) within previous 30 day plan index procedure . 13 . Subject stroke within previous 30 day plan index procedure and/or deficit prior stroke limit subject 's ability walk . 14 . Subject unstable angina define rest angina ECG change . 15 . Subject groin infection , acute systemic infection treat successfully currently treatment . 16 . Subject acute thrombophlebitis deep vein thrombosis either extremity . 17 . Subject medical illness ( e.g. , cancer congestive heart failure ) may cause subject noncompliant protocol requirement , confound data interpretation associate limited lifeexpectancy , i.e. , less 12 month . 18 . Subject currently participate investigational drug , biologic , device study complete primary endpoint clinically interfere current study endpoint . ( Note : Trials require extend followup product investigational , since become commercially available , consider investigational trial . ) 19 . Subject unable understand unwilling cooperate study procedure . 20 . Subject require general anesthesia procedure . 21 . Subject ischemic neuropathic ulcer either foot . 22 . Subject prior minor major amputation either low extremity . 23 . Subject part vulnerable population , judgment investigator , unable give inform consent reason incapacity , immaturity , adverse personal circumstance lack autonomy . This may include : Individuals mental disability , person nurse home , child , impoverished person , subject emergency situation , homeless person , nomad , refugee , incapable give informed consent . Vulnerable population also may include member group hierarchical structure university student , subordinate hospital laboratory personnel , employee sponsor , member arm force , person keep detention . Angiographic Exclusion Criteria 1 . Contralateral lesion distal location inguinal ligament require treatment within 30 day procedure . ( Contralateral iliac artery lesion may treat procedure necessary contralateral approach target lesion ) . 2 . Target extremity angiographically significant ( &gt; 50 % DS ) lesion locate distal target lesion . 3 . Acute ischemia target extremity 4 . Target extremity previously treat follow : surgical bypass endarterectomy . 5 . Target vessel previously treat following : stent , laser , atherectomy , surgical bypass , endarterectomy . 6 . Total occlusion ( 100 % DS ) ipsilateral inflow artery . 7 . Angiographic evidence thrombus target vessel . 8 . The target lesion require treatment device percutaneous transluminal angioplasty ( PTA ) ( e.g . limited , directional atherectomy , excimer laser , rotational atherectomy , brachytherapy , cryoplasty , etc . ) 9 . Target lesion within adjacent aneurysm . 10 . Subject angiographic evidence thromboembolism atheroembolism treatment ipsilateral iliac lesion , cross predilating target lesion . 11 . Target lesion moderatetosevere calcification either follow characteristic : Circumferential orientation Thickness &gt; 2 mm either radial longitudinal direction 12 . Subject abdominal aortic aneurysm &gt; 3 cm history aortic revascularization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>